By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – SomaLogic said Tuesday that it has signed a multi-year research agreement with Novartis, under which the drug firm will use SomaLogics' proteomics technology to accelerate its drug discovery and development efforts.

Larry Gold, CEO of Boulder, Colo.-based SomaLogic, said in a statement that the alliance will help Novartis "define robust biomarkers, validate novel drug targets, and even develop companion clinical diagnostics."

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Researchers describe a way to share data while keeping it secure, Agence France Presse reports.

In Science this week: genetic mutations typically associated with esophageal cancer are common in older, healthy individuals, and more.

India's Council of Scientific and Industrial Research has a new director-general, according to ScienceInsider.

A new study links more than a hundred genes to autism spectrum disorder, Discover's D-brief blog reports.

Nov
15
Sponsored by
Twist Bioscience

This webinar will discuss how Amyris, a biotechnology company that develops renewable products for a broad range of applications and industries, uses large-scale microbial engineering to support its manufacturing processes.